Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 350 of 1958 results for news

  1. Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)

    This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.

  2. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma

    In development Reference number: GID-IPG10067 Expected publication date: TBC

  3. Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (HTG518)

    Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.

  4. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  5. Early value assessment interim statement (PMG39)

    This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need

  6. Social care quick guides

    We've recently launched a new NICE website. Following a content review, a number of pages and sections have not moved onto the...

  7. Endometriosis: diagnosis and management (NG73)

    This guideline covers diagnosing and managing endometriosis, including where fertility is a priority. It aims to raise awareness of endometriosis symptoms, and to provide clear advice on referral, diagnosis and the range of treatments available.

  8. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

    Evidence-based recommendations on implantable cardioverter defibrillators and cardiac resynchronisation therapy for people with ventricular arrhythmias or heart failure

  9. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  10. Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)

    Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.

  11. Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

    Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

  12. Irritable bowel syndrome in adults: diagnosis and management (CG61)

    This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.

  13. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  14. Chronic obstructive pulmonary disease in adults (QS10)

    This quality standard covers assessing, diagnosing and managing chronic obstructive pulmonary disease (COPD). It describes high-quality care in priority areas for improvement.

  15. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

    Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.

  16. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

  17. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  18. Healthcare-associated infections (QS113)

    This quality standard covers preventing and controlling infections in hospitals and other secondary care settings that develop because of treatment or from being in a healthcare setting (healthcare-associated infections). It includes monitoring, responsibilities, and policies and procedures in secondary care organisations to reduce the risk of infection in patients, staff and visitors. It describes high-quality care in priority areas for improvement.

  19. Workplace health: long-term sickness absence and capability to work (QS202)

    This quality standard covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence. It covers everyone aged over 16 in full-time or part-time employment (paid or unpaid). It describes high-quality care in priority areas for improvement.

  20. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (TA1048)

    Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.

  21. Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)

    Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.

  22. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.

  23. Mental health of adults in contact with the criminal justice system (NG66)

    This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.

  24. Genicular artery embolisation for pain from knee osteoarthritis (HTG595)

    Evidence-based recommendations on genicular artery embolisation for pain from knee osteoarthritis. This involves inserting a tube through an artery in the groin into the genicular artery, and injecting tiny particles through it to block new blood vessels.

  25. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  26. VER-01 for treating chronic low back pain [ID6638]

    In development Reference number: GID-TA11842 Expected publication date: TBC

  27. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

    This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.

  28. Psychosis and schizophrenia in adults: prevention and management (CG178)

    This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.

  29. Artificial intelligence technologies for mammography: early value assessment

    Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC

  30. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

    Awaiting development Reference number: GID-TA10972 Expected publication date: TBC

  31. International collaboration

    International collaboration with NICE

  32. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input

  33. How we support healthtech commissioning

    provide additional support for funding and adoption. Subscribe to NICE news for health and social care newsletter Stay informed about...

  34. Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis (HTG592)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis in adults. This involves inserting a new valve inside a failed bioprosthetic valve to replace the faulty one without needing repeat open heart surgery.

  35. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  36. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

    Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.

  37. Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

    Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention for treating acute coronary syndromes in adults.

  38. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.

  39. Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable.

  40. Padeliporfin for untreated localised prostate cancer (TA546)

    Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.

  41. Oral health promotion: general dental practice (NG30)

    This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.

  42. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.

  43. Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

    Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.

  44. Interventional procedures programme manual (PMG28)

    This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual

  45. Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

    Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

  46. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

  47. Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

    Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

  48. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

  49. Miniature lens system implantation for advanced age-related macular degeneration (HTG418)

    Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens system into 1 eye only.